NASDAQ$QTRX
Quanterix Corporation · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Quanterix reported a strong quarter of growth driven by advances in Alzheimer's, MS, and COVID testing.
Quanterix announced financial results for Q3 2020, highlighting a strong quarter of growth despite pandemic-related headwinds. The company launched new Neurology assays, secured an NIH contract for SARS-CoV-2 Antigen test development, entered a non-exclusive IVD license agreement with Abbott, initiated surveillance studies, and raised nearly $100 million in capital.
- Made advances in Alzheimer’s, MS and COVID testing.
- Launched Neurology assays including pTau-181 and a comprehensive N4PE four plex.
- Secured an $18.2M NIH RADx contract to accelerate development, manufacturing scale-up and deployment of novel high-throughput SARS-CoV-2 Antigen test.
- Entered a non-exclusive IVD license agreement with Abbott.
Headline financials
Revenue & EPS history
Quanterix · Revenue · Quarterly
$31.4M
Revenue by segment
Quanterix · $20.4M total across 3 segments · Q3 2023
- Product Revenue$19.7M—96.4%
- Grant Revenue$499K—2.4%
- Collaboration and License$237K—1.2%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-3.6%
Avg return
Earnings day
-5.0%
Avg return
5 days after
-1.1%
Avg return
30 days after
30%
10 / 33 earnings
Positive
+18.1%
Q3 2020
Best reaction
-57.3%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | -15.2% | -0.6% | |
| Q4 2025 | -7.1% | -20.1% | -40.1% | |
| Q3 2025 | -2.0% | +12.1% | +47.5% | |
| Q1 2025 | -19.3% | -16.4% | +8.0% | |
| Q4 2024 | -1.8% | -0.8% | -29.3% | |
| Q3 2024 | -19.0% | -25.3% | -27.1% | |
| Q2 2024 | -13.5% | -11.7% | -5.0% | |
| Q1 2024 | -1.7% | -0.7% | -7.0% | |
| Q4 2023 | -2.8% | +20.1% | +0.3% | |
| Q3 2023 | -1.7% | -10.6% | +1.2% | |
| Q2 2023 | +11.0% | +9.5% | +15.4% | |
| Q1 2023 | +1.9% | -6.8% | +33.5% | |
| Q4 2022 | +5.9% | -1.4% | -1.6% | |
| Q3 2022 | -2.1% | +31.4% | +35.9% | |
| Q2 2022 | -57.3% | -40.1% | -45.8% | |
| Q1 2022 | -16.6% | +1.6% | -6.1% | |
| Q4 2021 | -3.1% | -11.9% | -13.5% | |
| Q3 2021 | +3.1% | -1.5% | -32.6% | |
| Q2 2021 | -5.0% | -6.7% | -6.4% | |
| Q1 2021 | +0.7% | -10.2% | +3.4% | |
| Q4 2020 | -20.8% | -18.5% | -25.7% | |
| Q3 2020 | +18.1% | +6.9% | +11.5% | |
| Q2 2020 | +8.5% | +2.6% | +1.3% | |
| Q1 2020 | +3.8% | -3.5% | -4.1% | |
| Q4 2019 | -7.0% | -20.3% | +7.8% | |
| Q3 2019 | +16.8% | +10.2% | +23.8% | |
| Q2 2019 | -5.4% | -17.5% | -17.3% | |
| Q1 2019 | -4.0% | -8.5% | +28.0% | |
| Q4 2018 | -1.1% | -2.7% | +10.3% | |
| Q3 2018 | -0.1% | -4.6% | +7.0% | |
| Q2 2018 | -1.3% | -0.5% | -0.9% | |
| Q1 2018 | +4.0% | +3.5% | -7.4% | |
| Q4 2017 | -1.2% | -8.6% | -1.7% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro